Glucagon-like peptide-1 (GLP-1) analogues

GLP1ANA

No definition available.

Endpoint definition

FinnGen phenotype data

321302 individuals

diagram downward connector

Apply sex-specific rule None

321302

diagram downward connector

Check conditions None

321302

diagram downward connector
diagram bullet

Filter registries

Medicine purchases: ATC A10BH

16740

diagram downward connector

Check pre-conditions, main-only, mode, ICD version None

14480

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

14480

diagram downward connector

Include endpoints None

14480

diagram downward connector
GLP1ANA

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

Key figures

All Female Male
?
Number of individuals
14022 6166 7856
?
Unadjusted prevalence (%)
4.54 3.55 5.82
?
Mean age at first event (years)
65.34 64.90 65.68

?
Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.05 3.86 [3.27, 4.57] 4.9e-56 1288
15 years 0.01 1.19 [0.99, 1.44] 6.8e-2 386
5 years 0.00 4.55 [3.88, 5.34] 9.5e-78 771
1 year 0.00 3.87 [3.10, 4.83] 5.7e-33 132

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: GLP1ANA – Glucagon-like peptide-1 (GLP-1) analogues
GWS hits:

Survival analyses between endpoints

Plot

before Glucagon-like peptide-1 (GLP-1) analogues
after Glucagon-like peptide-1 (GLP-1) analogues

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Glucagon-like peptide-1 (GLP-1) analogues